Clinical Trials Logo

Clinical Trial Summary

This study aims at elucidating the mechanism of clinical efficacy of ianalumab

Clinical Trial Description

This is an open-label, non-randomized, biopsy-based mechanistic study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05124925
Study type Interventional
Source Novartis
Contact Novartis Pharmaceuticals
Phone +41613241111
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date January 26, 2022
Completion date August 5, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03839069 - Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis N/A
Completed NCT03865888 - Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome Phase 3
Completed NCT02257957 - Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye Phase 3
Not yet recruiting NCT04988087 - A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD) Phase 2
Completed NCT01647737 - Green Tea Lozenges for the Management of Dry Mouth Phase 1/Phase 2
Recruiting NCT02450396 - Pregnancy and Medically Assisted Conception in Rare Diseases
Active, not recruiting NCT02132585 - Cross-sectional Study of Use of Speckle Method in Early Diagnosis of Cardiovascular Dysfunction N/A
Completed NCT01850979 - Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Phase 4
Recruiting NCT03816345 - Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Phase 1